Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 629-715-1 | CAS number: 1226892-43-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://echa.europa.eu/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Endpoint summary
Administrative data
Description of key information
Acute toxicity: Oral LD50 > 2000 mg/kg for rat (LD50 cut-off: 2500 mg/kg bw). No acute dermal and inhalation toxicity studies were performed on the substance due to its corrosive properties.
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: This study has been performed according to OECD and/or EC guidelines and according to GLP principles.
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.1 tris (Acute Oral Toxicity - Acute Toxic Class Method)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- acute toxic class method
- Limit test:
- no
- Species:
- rat
- Strain:
- other: Wistar strain Crl:WI (Han)
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Deutschland, Sulzfeld, Germany
- Age at study initiation: approximately 9-11 weeks
- Weight at study initiation: 153-195 g
- Fasting period before study: overnight until 3-4 hours after administration
- Housing: Group housing of 3 animals per cage in labeled Macrolon cages (MIV type; height 18 cm.) containing sterilized sawdust as bedding material and paper as cage-enrichment
- Diet (e.g. ad libitum): ad libitum
- Water (e.g. ad libitum): ad libitum
- Acclimation period: at least 5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 19.5 – 21.1
- Humidity (%): 44 - 78
- Air changes (per hr): approximately 15 air changes per hour
- Photoperiod (hrs dark / hrs light): 12/12
IN-LIFE DATES: From: 08 July 2009 To: 05 August 2009 - Route of administration:
- oral: gavage
- Vehicle:
- propylene glycol
- Details on oral exposure:
- VEHICLE
- Concentration in vehicle: 200 mg/ml (2000 mg/kg b.w.) or 30 mg/ml (300 mg/kg b.w.)
- Amount of vehicle (if gavage): 10 ml/kg b.w.
- Justification for choice of vehicle: based on trial formulations performed at NOTOX and on test substance data supplied by the sponsor
MAXIMUM DOSE VOLUME APPLIED:
10 ml/kg b.w.
CLASS METHOD (if applicable)
- Rationale for the selection of the starting dose: The starting dose of 300 mg/kg was based on toxicity expected for similar substances. - Doses:
- 300 and 2000 mg/kg
- No. of animals per sex per dose:
- 6 females
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: observations at least once daily. Weighing: weekly.
- Necropsy of survivors performed: yes
- Other examinations performed: no - Statistics:
- No statistical analysis was performed (The method used is not intended to allow the calculation of a precise LD50 value).
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- One female at 2000 mg/kg was found dead on Day 4. No (further) mortality occurred at 300 and 2000 mg/kg.
- Clinical signs:
- other: Clinical signs observed during the study period were as follows: Dose level Clinical signs 300 mg/kg Hunched posture, piloerection, lethargy, uncoordinated movements, rales, lean appearance and/or ptosis between Days 1 and 2; one female (no. 6) showed hun
- Gross pathology:
- One female at 300 mg/kg showed gaseous distension of the gastro-intestinal tract. No further macroscopic abnormalities were noted among other animals at 300 mg/kg.
Three females at 2000 mg/kg showed a stomach and right lateral lobe of the liver grown together with the diaphragm. No macroscopic abnormalities were noted in the other animals at 2000 mg/kg, including the female found dead on Day 4. - Interpretation of results:
- Category 5 based on GHS criteria
- Remarks:
- Migrated information
- Conclusions:
- The oral LD50 value of Tall oil diethylenetriamine imidazoline in Wistar rats was established to exceed 2000 mg/kg body weight.
According to the OECD 423 test guideline, the LD50 cut-off value was considered to be 2500 mg/kg body weight. - Executive summary:
Assessment of acute oral toxicity with Tall oil diethylenetriamine imidazoline in the rat (Acute Toxic Class Method).
The study was carried out based on the guidelines described in:
OECD No.423 (2001) "Acute Oral Toxicity, Acute Toxic Class Method"
Commission Regulation (EC) No 440/2008, B1 tris: "Acute Oral Toxicity, Acute Toxic Class Method"
EPA, OPPTS 870.1100 (2002), "Acute Oral Toxicity"
JMAFF guidelines (2000) including the most recent partial revisions.
Initially, Tall oil diethylenetriamine imidazoline was administered by oral gavage to three female Wistar rats at 300 mg/kg body weight. In a stepwise procedure additional groups of females were dosed at 300 and 2000 mg/kg body weight. All animals were subjected to daily observations and weekly determination of body weight. Macroscopic examination was performed on the day of death or after terminal sacrifice (Day 15).
One female at 2000 mg/kg was found dead on Day 4. No (further) mortality occurred at 300 and 2000 mg/kg.
Clinical signs observed during the study period were as follows:
300 mg/kg:
Hunched posture, piloerection, lethargy, uncoordinated movements, rales, lean appearance and/or ptosis between Days 1 and 2; one female showed hunched posture and rales throughout the observation period, along with lean appearance and piloerection on Day 15.
2000 mg/kg:
Hunched posture, piloerection and/or lethargy between Days 1 and 5.
One female at 300 mg/kg showed body weight loss throughout the observation period. Other animals at 300 mg/kg showed normal body weight gain.
One female at 2000 mg/kg found dead on Day 4 showed body weight loss between Days 1 and 4. Three other females at 2000 mg/kg showed no body weight gain or slight body weight loss between Days 1 and 8. Body weight gain among the (other) surviving females at 2000 mg/kg during the (remainder of the) observation period was considered to be normal.
One female at 300 mg/kg showed gaseous distension of the gastro-intestinal tract. No further macroscopic abnormalities were noted among other animals at 300 mg/kg.
Three females at 2000 mg/kg showed a stomach and right lateral lobe of the liver grown together with the diaphragm. No macroscopic abnormalities were noted in the other animals at 2000 mg/kg, including the female found dead on Day 4.
No explanation could be found for the differing macroscopic findings between the two treated groups at 2000 mg/kg.
The oral LD50 value of Tall oil diethylenetriamine imidazoline in Wistar rats was established to exceed 2000 mg/kg body weight.
According to the OECD 423 test guideline, the LD50 cut-off value was considered to be 2500 mg/kg body weight.
Reference
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 2 500 mg/kg bw
- Quality of whole database:
- Both available studies are guideline (OECD 423, ACT) studies performed under GLP
Acute toxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Tall oil + DETA was tested for acute oral toxicity in two different studies, both according to acute toxic class method. Both studies show the same outcome showing 1 resp. 2 deaths out of 6 dosed at 2000 mg/kg, and no mortality at 300 mg/kg.
At 300 mg clinical signs included Hunched posture, piloerection, lethargy, uncoordinated movements, hypersalivation, dyspnoea, and/or lean appearance, which in an incidental animal lasted until the end of the observation period.
Acute dermal toxicity: AAI are corrosive to the skin. Testing for acute dermal toxicity is therefore not justified. Toxicity following dermal exposure is characterised by local tissue damage, rather than the result of percutaneously absorbed material.
Acute inhalation toxicity: Also for acute inhalation toxicity information for classification is lacking, and is testing not justified. The likelihood of exposure via inhalation is low considering its high boiling point (> 300 °C) and very low vapour pressure (1.7 x 10-7 Pa at 25°C) and use applications that do not involve the forming of aerosols, particles or droplets of an inhalable size.
The substance is classified as corrosive and no acute toxicity testing should normally be conducted. As the substance is corrosive, symptoms of local respiratory irritation are expected, which should limit the systemic uptake of amount needed for systemic toxicity considering the relatively low acute oral toxicity.
Justification for classification or non-classification
For acute dermal and inhalation toxicity information for classification is lacking, and is testing not justified.
AAI are not aliphatic, alicyclic and aromatic hydrocarbons and have a relatively high viscosity and so do not indicate an immediate concern for aspiration hazard.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)